HIGHLIGHTS
- who: O from the Department Angiology, University Hospital Zurich, Zurich, Switzerland have published the paper: Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial, in the Journal: (JOURNAL)
- what: The primary outcome, the results of the 90-day data_analysis are consistent with those of the primary analysis focusing on the first 30 days of follow-up .
- how: For this 90-day follow-up study the authors analysed the changes in the prevalence of COVID-19-related symptoms in the two study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.